In vitro activity of voriconazole and other antifungal agents against clinical isolates of Candida glabrata and Candida krusei

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 23, Issue 8, 2004, Pages 619-624

  Drago, M ^a   Scaltrito, M M ^a   Morace, G ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA GLABRATA; CANDIDA KRUSEI; DRUG SENSITIVITY; FUNGUS ISOLATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDA GLABRATA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; HUMANS; ITALY; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; SAMPLING STUDIES; SENSITIVITY AND SPECIFICITY; TRIAZOLES;

EID: 4544386411     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-004-1174-9     Document Type: Article

References (16)

1. Koltin Y, Hitchccock CA (1997) The search for new triazole antifungal agents. Curr Opin Chem Biol 1:176-182
2. Sheehan DJ, Hitchcock CA, Sibley CM (1999) Current and emerging azole antifungal agents. Clin Microbiol Rev 12:40-79
3. Berrouane YF, Herwaldt LA, Pfaller MA (1999) Trends in antifungal use and epidemiology of nosocomial yeast infections in a university hospital. J Clin Microbiol 37:531-537
4. Maxwell MJ, Messer SA, Holler RJ, Boyken L, Tendolkar S, Diekema DJ, Pfaller MA, International Fungal Surveillance Participant Group (2003) Evaluation of E test method for determining fluconazole and voriconazole MICs for 279 clinical isolates of Candida species infrequently isolated from blood. J Clin Microbiol 41:1087-1090
5. Pfaller MA, Messer SA, Boyken L, Tendolkar S, Hollis RJ, Diekema DJ (2003) Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location. J Clin Microbiol 41:2176-2179
6. Morace G, Amato G, Bistoni F, Fadda G, Marone P, Montagna MT, Oliveri S, Polonelli L, Rigoli R, Mancuso I, La Face S, Masucci L, Romano L, Napoli C, Tatò D, Buscema MG, Belli CMC, Piccirillo MM, Conti S, Covan S, Fanti F, Cavanna C, D'Alò F, Pitzurra L (2002) A multicenter comparative evaluation of six commercial systems and the National Committee for Clinical Laboratory Standards M27-A broth microdilution method for fluconazole susceptibility testing of Candida species. J Clin Microbiol 40:2953-2958
7. Morace G, Polonelli L, GISIA Group (2003) A multicenter study of the in vitro activity of voriconazole against 1,996 yeast and 192 mould clinical isolates. In: Trends in medical mycology (Abstracts of the 9th congress of the European confederation of medical mycology and 7th trends in invasive fungal infections - joint meeting). Abstract no. O3.01
8. National Committee for Clinical Laboratory Standards (2002) Reference method for broth dilution antifungal susceptibility testing of yeasts. Revised approved standard M27-A2. NCCLS, Wayne
9. Barry AL, Pfaller MA, Brown SD, Espinel-Ingroff A, Ghannoum MA, Knapp C, Rennie RP, Rex JH, Rinaldi MG (2000) Quality control limits for broth microdilution susceptibility tests often antifungal agents. J Clin Microbiol 38:3457-3459
10. Rex JR, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff A, Ghannoum MA, Lancaster M, Odds FC, Rinaldi MG, Walsh TJ, Barry AL (1997) Development of interpretative breakpoints for antifungal susceptibility testing: conceptual framework, and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis 24:235-247
11. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Diekema DJ (2002) In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob Agents Chemother 46:1723-1727
12. Marr KA (2002) Empirical antifungal therapy - new options, new tradeoffs. N Engl J Med 346:278-280
13. White TC, Marr KA, Bowden RA (1998) Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 11:382-402
14. Pfaller MA, Diekema DJ, Jones RN, Messer SA, Hollis RJ, SENTRY participants group (2002) Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY antimicrobial surveillance program, 1997 to 2000. J Clin Microbiol 40:852-856
15. Pfaller MA, Diekema DJ, Boyken L, Messer SA, Tendolkar S, Hollis RJ (2003) Evaluation of the E test and disk diffusion methods for determining susceptibilities of 235 bloodstream isolates of Candida glabrata to fluconazole and voriconazole. J Clin Microbiol 41:1875-1880
16. Sanglard D (2002) Resistance of human fungal pathogens to antifungal drugs. Curr Opin Microbiol 5:379-385